HIPPOCAMPAL SPARING RADIOTHERAPY IN LUNG CANCER PATIENTS REQUIRING CRANIAL IRRADIATION

A PROSPECTIVE STUDY TO ASSESS THE FEASIBILITY OF HIPPOCAMPAL SPARING RADIOTHERAPY IN LUNG CANCER PATIENTS REQUIRING CRANIAL IRRADIATION - HSWBRT-LC

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037362

Enrollment

Registered

2021-10-18

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C30-C39- Malignant neoplasms of respiratory and intrathoracic organs

Interventions

Intervention1: Hippocampal sparing radiotherapy technique in lung cancer patients receiving WBRT for prophylactic or therapeutic purposes.: The study will also evaluate intracranial relapse rate in pa

Eligibility

Inclusion criteria

Inclusion criteria: 1) Histopathological proven Small Cell Lung Carcinoma. 2) Histopathological proven Non Small Cell Lung Carcinoma with BM. 3) Patient with BM with more than 5mm from hippocampus on CEMRI Brain 4) No prior history of radiation 5) Age >=18 years 6) KPS >= 70

Exclusion criteria

Exclusion criteria: 1) Patient with leptomenigeal metastasis 2) Patient with extracranial metastasis >= 2 site 3) Contraindicated to MRI 4) Prior radiation to brain 5) Severe active co morbidities such as Unstable angina, congestive heart failure, Hepatic insufficiency , Uncontrolled cardiac arrhythmias and Radiologic evidence of hydrocephalus. 6) Age 7) Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Evaluate neurocognitive decline at 2nd, 4th, 6th and 9th month following completion of HSWBRTTimepoint: Evaluate neurocognitive decline at 2nd, 4th, 6th and 9th month following completion of HSWBRT	—

Secondary

Measure	Time frame
1) Evaluate time to progression (TTP) radiologically in BM patients and intracranial relapse rates in patients receiving PCI after completion of HS-WBRT 2) Evaluate overall survival after completion of HS-WBRT 3) Evaluate adverse events during radiation according to CTCAE. 4) To find out the incidence and location of BM following HSWBRT in the prophylactic setting. 5) Quality of life measurement at 2nd, 4th, 6th and 9th month post HSWBRT. Timepoint: 2 MONTHS 4MONTHS 6MONTHS 9MONTHS	—

Measure

Time frame

1) Evaluate time to progression (TTP) radiologically in BM patients and intracranial relapse rates in patients receiving PCI after completion of HS-WBRT 2) Evaluate overall survival after completion of HS-WBRT 3) Evaluate adverse events during radiation according to CTCAE. 4) To find out the incidence and location of BM following HSWBRT in the prophylactic setting. 5) Quality of life measurement at 2nd, 4th, 6th and 9th month post HSWBRT. Timepoint: 2 MONTHS 4MONTHS 6MONTHS 9MONTHS

—

Countries

India

Contacts

Public ContactDR DIVYA KHOSLA

PGIMER

dr_divya_khosla@yahoo.com9876638478

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026